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ABSTRACT 
Improvements in survival due to advances in antiretroviral therapy (ART) have led to a shift in 
the age distribution of those receiving HIV care, with increasing numbers of women living with 
HIV (WLWHIV) reaching menopausal age.  We present a narrative literature review of 26 
studies exploring the menopause transition in WLWHIV, focusing on: (1) natural history (2) 
symptomatology and management, and (3) immunologic and virologic effects.   
Data are conflicting on the association between HIV and earlier age at menopause, and the role 
of HIV-specific factors such as HIV viral load and CD4 count.  There are some data to suggest 
that WLWHIV experience more vasomotor and psychological symptoms during the menopause 
than HIV-negative women, and that uptake of hormone replacement therapy by WLWHIV is 
comparatively low.  There is no evidence that menopause affects either CD4 count or response 
to ART, although there may be increased immune activation in older WLWHIV. 
We conclude that menopause in WLWHIV is a neglected area of study.  Specific information 
gaps include qualitative studies on experiences of reproductive ageing; data on the impact of 
the menopause on women’s quality of life and ability to adhere to health-sustaining behaviors; 
as well as studies investigating the safety and efficacy of pharmacological and psychosocial 
interventions.  There is likely to be a burden of unmet health need among this growing 
population, and better data are required to inform optimal provision of care, supporting WLWHIV 
to maintain their health and wellbeing into their post-reproductive years. 
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1. INTRODUCTION 
In 2014, approximately 36.9 million people were living with HIV globally, of whom over half were 
women.  (http://www.unaids.org, accessed 07 January 2016).  Advancements in antiretroviral 
therapy (ART) have resulted in significant improvements in survival, such that people with well-
controlled HIV may expect a near normal life expectancy.(1) Increasing coverage of ART has 
therefore led to a shift in the demographic profile of the HIV epidemic, reflected in increasing 
HIV prevalence rates among older people.(2)   In 2014 nearly 25,100 people aged 50 and over 
attended clinical services for HIV-related care in the United Kingdom (UK), a four-fold increase 
since 2005.  Approximately 8700 women of potentially menopausal age (i.e. between 45 and 56 
years) attended for HIV-related care in the UK in 2014 (Zheng Yin, Public Health England, 
personal communication, 26/02/16).  Based on the observed age distribution of women 
attending for HIV care in the UK in 2013, a total of 10,000 women are likely to reach potentially 
menopausal age in the next ten years (Zheng Yin, Public Health England, personal 
communication, 25/02/2016).(3) 
A consequence of living longer with HIV is the increased likelihood of developing age-related 
conditions.  For women living with HIV (WLWHIV) entering their midlife, this includes transition 
through the menopause.  In the shorter term, it is known that the menopause transition is 
frequently associated with a range of physical and psychological changes. Approximately 85% 
of women report symptoms such as hot flushes, sleep disturbance and mood changes,(4) with 
vasomotor symptoms lasting a median duration of 7.4 years.(5) Menopausal symptoms impact 
negatively upon women's quality of life, their role performance at work, and their 
relationships.(6, 7)  Furthermore, the loss of the protective effects of estrogen brings an 
attendant risk of longer-term conditions such as dyslipidemia, osteoporosis and cardiovascular 
disease, which is likely to be of particular significance for WLWHIV as the risk of developing 
these conditions is elevated in the context of HIV infection.(8)    
Gonadal dysfunction is well-described in HIV-positive men, and ovarian dysfunction has been 
reported in WLWHIV.(9)  The mechanisms for this remain unclear but may include: (i) direct 
effects of the virus itself, (ii) the effects of chronic inflammation on the neuroendocrine axis, (iii) 
effects of ART, and (iv) co-existing factors such as smoking, low body mass, or substance 
misuse.   This may alter the natural history and/or symptomatology of the menopause in 
WLWHIV.  Transitioning through the menopause in the context of chronic illness may present 
additional challenges in terms of ascertaining symptom etiology, with evidence to suggest that 
menopause-related symptoms in WLWHIV are under-recognized by healthcare providers.(10) 
We present a narrative review of literature on the menopause in WLWHIV.  Although noting the 
growing body of literature on the effects of reproductive ageing on risk of bone disease in 
WLWHIV, we feel this merits a review of its own and is therefore outside the scope of this 
paper.  Our specific objectives were to summarize data in WLWHIV on the following: (1) the 
natural history of the menopause, (2) symptomatology of the menopause transition and its 
management, and (3) the immunologic and virologic effects of the menopause transition.   
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2. METHODS 
2.1 Data extraction 
We undertook a comprehensive literature search in December 2015 using the following online 
databases: PubMed, Embase, CINAHL, and Web of Science.  Our aim was to identify original 
research papers that explored menopause in WLWHIV.  Search terms used to identify literature 
included: climacteric, menopaus*, pre-menopaus*, post-menopaus*, “pre menopaus*” and “post 
menopaus*”, all in combination with HIV.  We applied these search terms to abstracts and title 
in all databases, and restricted all searches to studies in human females only.  There was no 
date restriction for any of the searches, and studies using any methodological approach were 
considered.  Our initial literature search identified 399 documents, of which 162 were primarily 
focused on the menopause in WLWHIV.  We reviewed these 162 documents, excluding review 
papers, non-English language publications, and studies that did not focus on any of our three 
key research questions.  In addition, bibliographies of review papers were cross-referenced and 
we hand-searched available abstracts for the following conferences: British HIV Association 
(BHIVA), Conference for Retroviruses and Opportunistic Infections (CROI), and the International 
AIDS Society (IAS).  The final number of studies included in this review is 26. 
3. RESULTS 
3.1 Natural history of the menopause in women living with HIV 
The average age at natural menopause in the UK is 52 years.(11)  Several cross-sectional 
studies in WLWHIV, almost all using self-reported menstrual pattern to categorize menopausal 
status, have reported a younger median age at menopause, ranging from 47.5 to 50 years 
(Table 1).(12-15)  Two prospective studies, including one of very few to have been conducted in 
Europe, have reported similar findings.(16, 17), suggesting that WLWHIV may experience 
menopause at an earlier age.  However, this is not supported by the only two studies that 
included an HIV-negative comparison group as part of their design, neither of which found any 
statistically significant difference in age at menopause by HIV serostatus.(18, 19)  One of these 
was an analysis of data from the Women’s Interagency HIV Study (WIHS), a United States (US) 
prospective observational cohort of women both living with, and at risk of, HIV infection.(19)   It 
is the largest study to date to compare age at menopause in HIV-positive and HIV-negative 
women, and the only one to use biological markers of ovarian function. 
Authors from Brazil and from the UK have reported a relatively high prevalence of menopause 
before 45 years of age in WLWHIV.(17, 20) The study from the UK, a small retrospective case 
notes review, found that 14% of 123 HIV-positive women attending their clinic aged 50 or older 
had experienced cessation of menstruation when they were younger than 45; half of these 
women had experienced premature ovarian insufficiency (POI), that is menopause at 40 years 
or younger.(20)  This is similar to the prevalence of POI in the general UK population, which is 
estimated to be 7.4%.(21)  Other authors have reported higher rates of POI in HIV-positive 
women, including 12% in a French cohort (16) and 26% in a US study, which found that POI 
was significantly more common in WLWHIV compared to their HIV-negative counterparts.(18) 
Recognized risk factors for earlier menopause such as smoking and substance misuse have 
been reported in studies of menopause in WLWHIV.(16-18)  Co-infection with HIV and hepatitis 
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C has also been shown to be associated with earlier menopause.(17) However, data on the 
association between direct HIV-related factors and either menopausal status or age at 
menopause are conflicting.  Some authors have found no association with CD4 Count, HIV viral 
load and the use of ART,(12, 14, 19) whereas lower CD4 count has been shown to be a risk 
factor by others.(16-18)  Evidence for a link between immunosuppression and menopause is 
further strengthened by data suggesting that lower CD4 count is associated with anovulatory 
cycles (22) and decreased levels of anti-mullerian hormone (AMH), a marker of ovarian 
reserve.(23)    Furthermore, deranged follicle-stimulating hormone (FSH) levels have been 
described both in HIV infection itself and with use of ART, which may affect the diagnostic value 
of FSH in this group of women.(24) 
3.2 Symptomatology and management of the menopause transition in women living with HIV 
 We identified 15 studies investigating symptomatology and management of the menopause in 
WLWHIV, the majority conducted in the US (Table 2).  Boonyanurak at al.,(12) in their study of 
HIV-positive women in Thailand, found that night sweats and loss of sexual desire were more 
prevalent in postmenopausal WLWHIV compared to those who were premenopausal.  One 
study has found no association between HIV-status and menopausal symptoms (including 
vasomotor, genitourinary and psychological symptoms),(25) whereas increased symptoms have 
been reported by other authors.(15, 26-29)   
 
Vasomotor symptoms are relatively well-investigated in WLWHIV.  The reported prevalence of 
vasomotor symptoms in HIV-positive women ranges from 64-87%, (14, 15, 25, 28-30) which is 
not dissimilar to the rate reported in women without HIV.(4)  Higher CD4 counts appear to be 
associated with increased symptoms in HIV-positive women.(13, 29)  HIV-infection has been 
found to be associated with increased prevalence, frequency and severity of vasomotor 
symptoms.(15, 28)  Looby et al. (27) followed 66 HIV-positive and HIV-negative perimenopausal 
women longitudinally over a 12-month period, observing an  increased severity of vasomotor 
symptoms in WLWHIV that persisted over time.  Analyses of data from both this study and from 
the WIHS cohort, demonstrate an association between severity and persistence of vasomotor 
symptoms, and elevated levels of depression in WLWHIV.(26, 31)  Another analysis of WIHS 
data also found that vasomotor symptoms were associated with decreased scores in cognitive 
measures, however there was no difference by HIV serostatus.(32)   
 
The prevalence of psychological symptoms (including depression and anxiety) in WLWHIV 
during the menopause transition ranges from 38% to over 95%,(15, 25, 26, 29, 31) with the 
variation likely to be largely due to the use of different outcome measures and differences in 
populations.  Although psychological symptoms such as depression are reported more 
frequently by women in the context of HIV regardless of menopausal status, both Ferreira at al. 
(15) and Looby et al. (26) report an association between HIV-infection and increased 
psychological symptoms around the time of the menopause even when adjusting for previous 
history of poor mental health.  In contrast, an analysis of WIHS data on 1170 women found that 
although depression is more prevalent among perimenopausal women when compared to 
premenopausal women, that this is not related to HIV serostatus.(31) 
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Genitourinary symptoms are common both peri- and postmenopausally.  It is estimated that the 
prevalence these symptoms in WLWHIV is 48-73%,(14, 15, 25, 29)  with Ferreira et al. (15) 
reporting an association with HIV-infection.  Decreased sexual function has been reported in 
WLWHIV at all ages, and has been shown to decline postmenopausally in women regardless of 
HIV serostatus.(33)  Only one study has investigated dyspareunia in midlife WLWHIV, 
describing a prevalence of 41% in WLWHIV aged 40-60 years, although this was not 
significantly different to the prevalence in the HIV-negative comparison group.(34) 
 
We found very few studies that sought to explore management of the menopause in WLWHIV, 
and none that assessed efficacy or safety of interventions.  Small studies have revealed low 
rates of hormone replacement therapy (HRT) use among WLWHIV, with estimated usage 
ranging from 0-11%.(13, 14, 20, 30)  This may be related to limited awareness of the 
menopause within this patient group.(30) 
   
3.3 Immunologic and virologic effects of the menopause transition in women living with HIV 
The immunomodulatory effects of estrogen is well-recognized,(35) making the effects of 
estrogen depletion on the natural history of HIV-infection of particular interest.  We identified 
four studies that investigate this (Table 3).  Comparing postmenopausal HIV-positive and HIV-
negative women, Alcaide et al. (36) report higher levels of immune activation and microbial 
translocation in older WLWHIV, which  appear to correlate with biomarkers of cardiovascular 
disease and cognitive impairment.(36)  However, there is no evidence thus far of an effect of 
menopausal status on either CD4 count decline post-seroconversion to HIV,(37) or immunologic 
or virologic response to ART.(38, 39).   
 
4. CONCLUSION 
 
Despite the growing numbers of women living with HIV who are transitioning through the 
menopause, existing data is scanty and frequently contradictory. Much of the available data 
comes from the USA, where the populations of women affected by HIV differ from those in 
Europe and the UK, making comparisons across studies and data sets problematic. The 
influence of viral activity and immune suppression as evidenced by the HIV viral load and CD4 
count respectively on ovarian function may be an important consideration on the timing of 
menopause, although uncertainty remains about the impact of HIV on age at menopause.   As 
HIV and its treatments can predispose to a variety of metabolic complications, many of which 
are also associated with ageing, the implications of menopausal changes for women with HIV 
are significant.   Data on best management strategies for HIV-positive menopausal women are 
lacking, Despite UK recommendations that HRT should be discussed and offered to 
menopausal women,(40) there appear to be low rates of use by women living with HIV, with the 
reasons underlying  this unknown.  Given the complexity of the lives of women living with HIV, 
understanding the additional impact of menopause on quality of life, and women’s abilities to 
engage with health-sustaining behaviors including adherence to ART and retention in care, are 
important issues for future research. There is likely to be a significant burden of unmet health 
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needs among menopausal women living with HIV making a better understanding of the impact 
and best practice approaches to management an important priority for future investigation.  
 
Contributors: 
ST designed the literature search and drafted the first version of this article.  Both ST and JA 
selected the final studies to be included in this review.  VD provided epidemiological data from 
the UK.  All authors critically reviewed the first version of the article and approved the final draft 
for publication. 
Conflicts of interest: 
ST has previously received a travel bursary funded by Janssen-Cilag through the British HIV 
Association.   ST and JA are members of the steering group of SWIFT, a networking group for 
people involved in research in HIV and women, funded by Bristol Myers Squibb.   
Funding: 
ST is funded by the National Institute of Health Research (NIHR) in the form of a postdoctoral 
fellowship (PDF-2014-07-071).  Any views expressed in this paper are those of the authors, and 
not necessarily those of the funders.   
8 
 
REFERENCES 
 
1. Mocroft A, Lundgren JD, Sabin ML, Monforte A, Brockmeyer N, Casabona J, et al. Risk 
Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from 
the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). 
PLoS Med. 2013;10(9):e1001510. 
2. Mahy M, Autenrieth CS, Stanecki K, Wynd S. Increasing trends in HIV prevalence 
among people aged 50 years and older: evidence from estimates and survey data. AIDS. 2014. 
3. Yin Z, editor Over Half of People in HIV Care in the United Kingdom by 2028 Will Be 
Aged 50 Years or Above. 15th European AIDS Conference; 2015; Barcelona, Spain. 
4. McKinlay SM, Brambilla DJ, Posner JG. The normal menopause transition. Maturitas. 
1992;14(2):103-15. 
5. Avis NE, Crawford SL, Greendale G, Bromberger JT, Everson-Rose SA, Gold EB, et al. 
Duration of Menopausal Vasomotor Symptoms Over the Menopause Transition. JAMA Internal 
Medicine. 2015. 
6. Williams RE, Levine KB, Kalilani L, Lewis J, Clark RV. Menopause-specific 
questionnaire assessment in US population-based study shows negative impact on health-
related quality of life. Maturitas. 2009;62(2):153-9. 
7. Woods NF, Mitchell ES. Symptom interference with work and relationships during the 
menopausal transition and early postmenopause: observations from the Seattle Midlife 
Women's Health Study. Menopause. 2011;18(6):654-61. 
8. Looby SE. Menopause-associated metabolic manifestations and symptomatology in HIV 
infection: a brief review with research implications. J Assoc Nurses AIDS Care. 2012;23(3):195-
203. 
9. Yalamanchi S, Dobs A, Greenblatt RM. Gonadal function and reproductive health in 
women with human immunodeficiency virus infection. Endocrinol Metab Clin North Am. 
2014;43(3):731-41. 
10. Cejtin HE, Kim S, Taylor RN, Watts DH, editors. Assessment of menopausal status 
among women in the Women's Interagency HIV Study (WIHS). The XV International AIDS 
Conference; 2004; Bangkok. 
11. The British Menopause Society. Premature Menopause 2013 [cited 2013 29 October]. 
Available from: http://www.thebms.org.uk/factdetail.php?id=1. 
12. Boonyanurak P, Bunupuradah T, Wilawan K, Lueanyod A, Thongpaeng P, Chatvong D, 
et al. Age at menopause and menopause-related symptoms in human immunodeficiency virus-
infected Thai women. Menopause. 2012;19(7):820-4. 
13. Clark RA, Cohn SE, Jarek C, Craven KS, Lyons C, Jacobson M, et al. Perimenopausal 
symptomatology among HIV-infected women at least 40 years of age. J Acquir Immune Defic 
Syndr. 2000;23(1):99-100. 
14. Fantry LE, Zhan M, Taylor GH, Sill AM, Flaws JA. Age of menopause and menopausal 
symptoms in HIV-infected women. AIDS Patient Care STDS. 2005;19(11):703-11. 
15. Ferreira CE, Pinto-Neto AM, Conde DM, Costa-Paiva L, Morais SS, Magalhaes J. 
Menopause symptoms in women infected with HIV: prevalence and associated factors. 
Gynecological endocrinology : the official journal of the International Society of Gynecological 
Endocrinology. 2007;23(4):198-205. 
16. de Pommerol M, Hessamfar M, Lawson-Ayayi S, Neau D, Geffard S, Farbos S, et al. 
Menopause and HIV infection: age at onset and associated factors, ANRS CO3 Aquitaine 
cohort. Int J STD AIDS. 2011;22(2):67-72. 
9 
 
17. Calvet GA, Grinsztejn BG, Quintana Mde S, Derrico M, Jalil EM, Cytryn A, et al. 
Predictors of early menopause in HIV-infected women: a prospective cohort study. American 
Journal of Obstetrics and Gynecology. 2015;212(6):765 e1- e13. 
18. Schoenbaum EE, Hartel D, Lo Y, Howard AA, Floris-Moore M, Arnsten JH, et al. HIV 
infection, drug use, and onset of natural menopause. Clin Infect Dis. 2005;41(10):1517-24. 
19. Cejtin HE, Kim S, Taylor RN, Minkoff HL, Massad LS, Preston-Martin S, et al., editors. 
Menopause in women in the Women's Interagency HIV Study (WIHS). The XV International 
AIDS Conference; 2004; Bangkok. 
20. Samuel M, Welch J, Tenant-Flowers M, Poulton M, Campbell L, Taylor C. Care of HIV-
positive women aged 50 and over - can we do better? Int J STD AIDS. 2013. 
21. Islam R, Cartwright R, editors. The impact of premature ovarian failure on quality of life: 
results from the UK 1958 Birth Cohort. Human Reproduction; 2011: Oxford University Press. 
22. Clark RA, Mulligan K, Stamenovic E, Chang B, Watts H, Andersen J, et al. Frequency of 
anovulation and early menopause among women enrolled in selected adult AIDS clinical trials 
group studies. J Infect Dis. 2001;184(10):1325-7. 
23. Scherzer R, Bacchetti P, Messerlian G, Goderre J, Maki PM, Seifer DB, et al. Impact of 
CD4+ lymphocytes and HIV infection on Anti-Mullerian Hormone levels in a large cohort of HIV-
infected and HIV-uninfected women. Am J Reprod Immunol. 2015;73(3):273-84. 
24. Santoro N, Arnsten JH, Buono D, Howard AA, Schoenbaum EE. Impact of street drug 
use, HIV infection, and highly active antiretroviral therapy on reproductive hormones in middle-
aged women. Journal of Women's Health (2002). 2005;14(10):898-905. 
25. Lui-Filho JF, Valadares AL, Gomes Dde C, Amaral E, Pinto-Neto AM, Costa-Paiva L. 
Menopausal symptoms and associated factors in HIV-positive women. Maturitas. 
2013;76(2):172-8. 
26. Looby S, Shifren JL, Corless I, Pedersen MC, Grinspoon S, Joffe H. Depressive 
symptoms in perimenopausal women with and without hiv. Menopause. 2013;20 (12):1341. 
27. Looby S, Shifren JL, Grinspoon S, Joffe H. Longitudinal assessment of menopause 
symptoms in perimenopausal women with HIV. Menopause. 2014;21 (12):1354. 
28. Looby SE, Shifren J, Corless I, Rope A, Pedersen MC, Joffe H, et al. Increased hot flash 
severity and related interference in perimenopausal human immunodeficiency virus-infected 
women. Menopause. 2014;21(4):403-9. 
29. Miller SA, Santoro N, Lo Y, Howard AA, Arnsten JH, Floris-Moore M, et al. Menopause 
symptoms in HIV-infected and drug-using women. Menopause. 2005;12(3):348-56. 
30. Hughes CA, Yuksel N, Foisy M. A survey on the severity and management of 
menopausal symptoms in middle-aged HIV-infected women. Canadian Journal of Infectious 
Diseases and Medical Microbiology. 2012;23:119A. 
31. Maki PM, Rubin LH, Cohen M, Golub ET, Greenblatt RM, Young M, et al. Depressive 
symptoms are increased in the early perimenopausal stage in ethnically diverse human 
immunodeficiency virus–infected and human immunodeficiency virus–uninfected women. 
Menopause. 2012;19(11):1215-23. 
32. Rubin LH, Sundermann EE, Cook JA, Martin EM, Golub ET, Weber KM, et al. 
Investigation of menopausal stage and symptoms on cognition in human immunodeficiency 
virus-infected women. Menopause. 2014;21(9):997-1006. 
33. Wilson TE, Jean-Louis G, Schwartz R, Golub ET, Cohen MH, Maki P, et al. HIV infection 
and women's sexual functioning. J Acquir Immune Defic Syndr. 2010;54(4):360-7. 
34. Valadares AL, Pinto-Neto AM, Gomes Dde C, D'Avanzo WC, Moura AS, Costa-Paiva L, 
et al. Dyspareunia in HIV-positive and HIV-negative middle-aged women: a cross-sectional 
study. BMJ Open. 2014;4(11):e004974. 
35. Gameiro C, Romao F. Changes in the immune system during menopause and aging. 
Frontiers in Bioscience. 2009;2:1299-303. 
10 
 
36. Alcaide ML, Parmigiani A, Pallikkuth S, Roach M, Freguja R, Della Negra M, et al. 
Immune activation in HIV-infected aging women on antiretrovirals--implications for age-
associated comorbidities: a cross-sectional pilot study. PloS one. 2013;8(5):e63804. 
37. van Benthem BH, Vernazza P, Coutinho RA, Prins M. The impact of pregnancy and 
menopause on CD4 lymphocyte counts in HIV-infected women. AIDS. 2002;16(6):919-24. 
38. Calvet GA, Velasque L, Luz PM, Cardoso SW, Derrico M, Moreira RI, et al. Absence of 
effect of menopause status at initiation of first-line antiretroviral therapy on immunologic or 
virologic responses: a cohort study from Rio de Janeiro, Brazil. PloS one. 2014;9(2):e89299. 
39. Patterson KB, Cohn SE, Uyanik J, Hughes M, Smurzynski M, Eron JJ. Treatment 
responses in antiretroviral treatment-naive premenopausal and postmenopausal HIV-1-infected 
women: an analysis from AIDS Clinical Trials Group Studies. Clin Infect Dis. 2009;49(3):473-6. 
40. National Institute for Health and Care Excellence (NICE). Menopause: diagnosis and 
management. National Institute for Health and Care Excellence (NICE), 2015 12 November. 
11 
 
Table 1: Natural history of the menopause in women living with HIV 
Reference Aims Sample Design Definition of menopause Findings 
12 To investigate age at 
natural menopause 
in WLWHIV 
 Thailand 
 268  WLWHIV  
 Aged ≥40  
  Cross-sectional 
  Questionnaire 
 ≥ 12 months without 
menstruation 
 55 women had reached menopause 
 Median age at menopause=47  
 Menopause associated with CDC 
stage but not CD4 count or HIV viral 
load 
13 To define menopause 
in WLWHIV 
 US 
 101 WLWHIV  
 Aged ≥40  
 Cross-sectional 
questionnaire 
 FSH>35 mU/ml or ≥ 6 
months without 
menstruation and aged 
≥55 years 
 50% were postmenopausal 
 Mean age at menopause= 47  
14 
 
 
 
 
 
To examine median 
age at menopause 
and factors 
associated with 
postmenopausal 
status in WLWHIV 
 US 
 120 WLWHIV  
 Aged 40-57  
 95% African-American 
 
 Cross sectional 
questionnaire study 
 LMP ≥1 year before 
enrolment 
 25% were postmenopausal 
 26% were perimenopausal 
 Median age at menopause=50  
 No association between 
menopausal status and CD4 count, 
HIV viral load or ART regimens. 
15 To evaluate 
prevalence of and 
factors associated 
with menopausal 
symptoms in 
WLWHIV 
 Brazil 
 96 HIV-positive; 155 HIV-
negative  
 Aged ≥40  
 
 Cross-sectional 
questionnaire 
 ≥ 12 months without 
menstruation 
 Median age at menopause for 
WLWHIV=48  
 16 To describe the 
characteristics of 
postmenopausal 
WLWHIV and to 
identify factors 
associated with 
earlier age at 
menopause 
 France 
 404 WLWHIV  
 
 
 Cross-sectional 
questionnaire study 
with prospective 
follow-up 
 ≥ 12 months without 
menstruation 
 17% postmenopausal at enrolment 
 Median age at menopause=49  
 12% reached natural menopause 
aged <40  
 African origin, history of IDU and 
CD4<200 associated with earlier 
age at menopause 
12 
 
 
Table 1: Natural history of the menopause in women living with HIV 
Reference Aims Sample Design Definition of menopause Findings 
17 To investigate age at 
natural menopause 
and its predictors in 
WLWHIV 
 Brazil 
 667 WLWHIV  
 Aged ≥30  
 Prospective 
observational cohort  
 LMP ≥1 year before 
enrolment 
 27% menopause aged <45  
 Median age at menopause=48  
 Younger age at menopause 
associated with  earlier menarche, 
smoking, chronic hepatitis C 
infection, and current CD4<50  
18 To study the 
association between 
HIV infection and 
substance misuse, 
and age at natural 
menopause 
 US 
 302 HIV-positive; 269 HIV-
negative  
 Aged 35-59  
 49% African American; 52% 
reported substance misuse 
 Cross-sectional 
questionnaire study 
with prospective 
follow-up 
 ≥ 12 months without 
menstruation 
 Median age at menopause in 
WLWHIV=46 (47 in HIV-negative 
women) 
 HIV-infection associated with 
menopause age <40  
 HIV-infection and substance misuse 
associated with being 
postmenopausal 
 Amongst WLWHIV, lower CD4 
count associated with 
postmenopausal status 
19 To compare 
menopause between 
HIV-positive and HIV-
negative women in 
the Women’s 
Interagency HIV 
Study (WIHS) 
 US 
 1062 HIV-positive; 273 HIV-
negative 
 Aged <55  
 
 Cross-sectional 
questionnaire study 
with serum samples 
 ≥6 months without 
menstruation AND FSH 
>25IU/ml 
 Median age at menopause in 
WLWHIV=47 years (48 years in HIV-
negative women) 
 No association between HIV 
infection and menopause 
 No association between 
menopause and CD4 count, HIV 
viral load, AIDS-related illness or 
use of ART 
20 To describe age-
specific health issues 
in WLWHIV aged ≥50 
years 
 UK 
 123 WLWHIV  
 Aged ≥50 
 91% on ART; 67% Sub-
Saharan African origin 
 Retrospective notes 
review 
 Not described  82% of women were 
postmenopausal 
 7% had menopause 40-44; 7% had 
menopause <40  
13 
 
 
Table 1: Natural history of the menopause in women living with HIV 
Reference Aims Sample Design Definition of menopause Findings 
22 To obtain 
information on 
prevalence of 
anovulation and early 
menopause in 
WLWHIV 
 US 
 52 HIV-positive  
 Aged 20-42  
 Testing of stored 
serum samples 
 Anovulation: 
Progesterone level ≤3.1  
ng/ml  
 Menopause: FSH >40 
mIU/ml  
 Anovulation=48% 
 Early menopause=8% 
 Higher CD4 associated with less 
change in menstrual pattern 
23 To describe 
associations between 
AMH levels and HIV-
related factors 
 US 
 2621 HIV-positive; 941 HIV-
negative  
 
 Longitudinal cohort 
study utilizing serum 
markers of ovarian 
function 
NA  Lower CD4 count associated with 
lower AMH levels 
 In adjusted analyses HIV-infection 
associated with higher AMH levels  
24 To assess impact of 
street drug use and 
HIV infection on 
reproductive 
hormones 
 US 
 82 HIV-positive; 15 HIV-
negative  
 Aged 18-56  
 46% reported substance 
misuse 
 Prospective cohort 
study utilizing serum 
markers of 
reproductive function 
 ≥ 12 months without 
menstruation 
 Substance misuse and HIV-infection 
associated with decreased FSH 
levels in postmenopausal women 
 ART associated with higher FSH 
WLWHIV, women living with HIV; LMP, last menstrual period; FSH, follicle-stimulating hormone; ART, antiretroviral therapy; IDU, injecting drug 
use; AMH, anti-mullerian hormone 
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Table 2: Symptomatology and management of the menopause transition in women living with HIV 
Reference Aims Sample Design Menopause definition Findings 
12 To investigate 
menopause 
related symptoms 
in WLWHIV 
 Thailand 
 268  WLWHIV   
 Aged ≥40  
 Cross-sectional 
 Questionnaire 
 LMP ≥1 year before 
enrolment 
 Postmenopausal WLWHIV had 
more night sweats and less sexual 
desire than premenopausal 
women 
13 To describe 
prevalence of 
perimenopausal 
symptomatology 
in WLWHIV 
 US 
 101 WLWHIV  
 Aged ≥40 years 
 26% CD4<200;20% not on 
ART 
 Cross-sectional 
questionnaire 
 FSH>35 mU/ml or ≥ 6 
months without 
menstruation and 
aged ≥55 years 
 Higher CD4 count associated with 
increased vasomotor symptoms 
 Higher HIV viral load associated 
with increased anxiety symptoms 
 Use of HRT=11% 
14 To evaluate the 
prevalence of 
menopausal 
symptoms in 
WLWHIV 
 US 
 120 WLWHIV  
 Aged 40-57  
 95% African-American 
 
 Cross-sectional 
questionnaire study 
 LMP ≥1 year before 
enrolment 
 Symptoms in WLWHIV: 
vasomotor=87%, 
genitourinary=53% 
 Use of HRT=10% 
15 To describe 
prevalence of and 
factors associated 
with menopausal 
symptoms in 
WLWHIV 
 Brazil 
 96 HIV-positive; 155 HIV-
negative  
 Aged ≥40  
 
 Cross-sectional 
questionnaire 
 ≥ 12 months without 
menstruation 
 Symptoms in WLWHIV: 
vasomotor=78%, 
psychological=98%, 
genitourinary=73% 
 HIV-infection associated with 
increased psychological, 
vasomotor and genitourinary 
symptoms  
20 To describe age-
specific health 
issues in WLWHIV 
aged ≥50 years 
 UK 
 123 WLWHIV  
 Aged ≥50  
 91% on ART; 67% Sub-
Saharan African origin 
 Retrospective notes 
review 
 Not described  Menopausal symptoms =28%  
 Use of HRT=10% 
15 
 
 
Table 2: Symptomatology and management of the menopause transition in women living with HIV 
Reference Aims Sample Design Menopause definition Findings 
25 To evaluate 
menopausal 
symptoms and 
associated factors 
in WLWHIV 
 Brazil 
 273 HIV-positive; 264 HIV-
negative  
 Aged 40-60  
 Cross-sectional 
questionnaire 
 ≥ 12 months without 
menstruation 
 Symptoms in WLWHIV: 
vasomotor=69%, psychological= 
83%, genitourinary=55% 
 No association between HIV 
status and vasomotor, 
psychological or genitourinary 
symptoms 
26 To evaluate 
depressive 
symptoms and 
correlates   in 
perimenopausal 
WLWHIV 
 US 
 33 HIV-positive; 33 HIV-
negative  
 Aged 45-52 
 Cross-sectional 
questionnaire 
 Perimenopause 
defined as one 
menstrual cycle longer 
in the prior 6 months, 
or irregular menses in 
≥2 cycles within  the 
past 6 months 
 Depression in women living with 
HIV=67% 
 HIV-infection associated with 
increased depression despite 
similar levels of prior depression  
 Increased depression associated 
with hot flush severity in both 
HIV-positive and HIV-negative 
women 
27 Longitudinal 
evaluation of 
menopausal 
symptoms in 
WLWHIV over 12 
months 
 US 
 33 HIV-positive; 33 HIV-
negative  
 Aged 45-52 
 Longitudinal 
questionnaire 
 Perimenopause=one 
menstrual cycle longer 
in the prior 6 months, 
or irregular menses in 
≥2 cycles within  the 
past 6 months 
 Greater burden of hot flushes, 
insomnia, anxiety and depression 
in WLWHIV persisted at 12 
months 
28 To evaluate hot 
flush severity and 
related 
interference 
among 
perimenopausal 
HIV-positive and 
HIV-negative 
women 
 US 
 33 HIV-positive; 33 HIV-
negative  
 Aged 45-52  
 Cross-sectional 
questionnaire with 
serum samples  
 Perimenopause=one 
menstrual cycle longer 
in the prior 6 months, 
or irregular menses in 
≥2 cycles within the 
past 6 months 
 Hot flushes ≥ 8 days in past 4 
weeks in WLWHIV=67% 
 HIV-infection associated with 
increased frequency and severity 
of hot flushes  
 FSH and estradiol levels similar in  
both HIV-positive and HIV-
negative women 
16 
 
Table 2: Symptomatology and management of the menopause transition in women living with HIV 
Reference Aims Sample Design Menopause definition Findings 
29 To examine the 
association of HIV 
infection, 
substance misuse 
and psychosocial 
stressors with 
menopausal 
symptoms 
 US 
 289 HIV-positive; 247 HIV-
negative  
 Aged ≥35 
 48% African American; 30% 
substance misuse 
 Cross-sectional study  ≥ 12 months without 
menstruation 
 Symptoms in WLWHIV: 
vasomotor=64%, psychological= 
90%, genitourinary=48% 
 HIV-infection associated with 
increased symptoms  
 Menopausal symptoms decreased 
as CD4 declined 
 Menopause symptoms in 
WLWHIV associated with receipt 
of public benefits   
 Increased menopause symptoms 
were associated with depressive 
symptoms in HIV-positive and 
HIV-negative women 
30 To evaluate the 
frequency and 
severity of 
menopausal 
symptoms in 
WLWHIV, and 
management of 
symptoms 
 Canada 
 31 WLWHIV  
 Aged 40-60  
 
 Cross-sectional 
questionnaire 
 Based on menstrual 
pattern but not 
described 
 Vasomotor symptoms in 
WLWHIV=72%  
 None had taken HRT 
 26% had received information 
about the menopause  
31 To evaluate the 
association of 
menopausal 
stage and 
vasomotor 
symptoms with 
depressive 
symptoms in 
women with a 
high prevalence 
of HIV 
 US 
 835 HIV-positive;335 HIV-
negative  
 Aged 30-65  
 
 Cross-sectional 
questionnaire 
 ≥ 12 months without 
menstruation 
 Depression in women living with 
HIV=38% 
 HIV-positive and HIV-negative 
women in early perimenopause at 
higher risk of depression  
 Persistent vasomotor symptoms 
associated with depression 
 Depression  in HIV-positive 
perimenopausal women was 
associated with not being on ART  
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Table 2: Symptomatology and management of the menopause transition in women living with HIV 
Reference Aims Sample Design Menopause definition Findings 
32 To examine the 
associations of 
menopausal 
stage, 
menopausal 
symptoms, HIV 
status and 
cognition 
 US 
 708 HIV-positive; 278 HIV-
negative  
 Aged 30-65  
 
 Cross-sectional 
questionnaire 
 ≥ 12 months without 
menstruation 
 HIV associated with poorer 
cognitive performance 
 Menopausal stage  not associated 
with cognition 
 Vasomotor symptoms were 
associated with poorer cognitive 
function in HIV-negative and 
WLWHIV 
33 To compare 
sexual function 
among HIV-
positive and HIV-
negative women 
 US 
 1279 HIV-positive; 526 HIV-
negative  
 Aged ≥20  
 Cross-sectional 
questionnaire  
 
• ≥ 12 months without 
menstruation 
 HIV-infection associated with 
reduced sexual function at all ages 
 Reduced sexual function 
associated with being 
postmenopausal in HIV-negative 
and WLWHIV 
34 To evaluate 
whether 
dyspareunia is 
associated with 
HIV status in 
menopausal 
women 
 Brazil 
 128 HIV-positive; 178 HIV-
negative  
 Aged 40-60 
 Cross-sectional 
questionnaire 
•  ≥ 12 months without 
menstruation 
 Dyspareunia in WLWHIV=41%% 
 No association between HIV-
infection and dyspareunia 
WLWHIV, women living with HIV; LMP, last menstrual period; ART, antiretroviral therapy; FSH, follicle-stimulating hormone; HRT, hormone 
replacement therapy 
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Table 3: Immunologic and virologic effects of the menopause transition in women living with HIV 
Study Aims Sample Design Menopause definition Findings 
36 To investigate 
immune 
activation and 
microbial 
translocation in 
WLWHIV of 
postmenopausal 
age 
 US 
 27 HIV-positive; 15 HIV-
negative 
 Aged >45 
 Cross-sectional study 
using biological 
markers 
 ≥ 12 months without 
menstruation 
 HIV-infection associated with 
immune activation and microbial 
translocation  
37 To determine the 
effect of 
pregnancy and 
menopause on 
CD4 counts in 
WLWHIV 
 12 European countries 
 382 WLWHIV with a known 
interval of seroconversion 
 Retrospective cohort 
study 
 Not described  No difference in CD4 count 3 
years post-seroconversion by 
menopausal status 
38 To compare 
effectiveness of 
1st line ART 
between 
premenopausal 
and 
postmenopausal 
WLWHIV 
 Brazil 
 383 WLWHIV (15% 
postmenopausal) 
 
 Longitudinal 
questionnaire study 
with serum samples 
 ≥ 12 months without 
menstruation 
 No difference in CD4 or virologic 
response by menopausal status 
39 To compare 
immunologic and 
virologic 
responses to 
initial ART by 
menopausal 
status 
 US 
 267 WLWHIV (18% 
postmenopausal) 
 Retrospective cohort 
study 
 ≥6 months without 
menstruation plus 
FSH >35 mIU/mL at 
any age 
 No difference in immunologic or 
virologic response to ART by 
menopausal status 
WLWHIV, women living with HIV; ART, antiretroviral therapy; FSH, follicle stimulating hormone 
 
